Biocryst Pharmaceuticals Inc. - BCRX- Profile

Biocryst Pharmaceuticals Inc. The Company's principal activity is to design, optimize and develop novel small molecule pharmaceuticals that block key enzymes essential for cancer, cardiovascular diseases, autoimmune diseases and viral infections. The Company's most advanced drug candidate, forodesine hydrochloride ('BCX-1777' or 'forodesine'), is an investigational purine nucleoside phosphorylase ('PNP') inhibitor for the treatment of T-cell mediated disorders. Some of the projects under development include PNP Inhibitor (forodesine HCl, BCX-1777), Oncology, PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, Tissue Factor/Factor VIIa Inhibitors. The Company markets its products through collaborators and licensees. Develops pharmaceuticals for cancer, cardiovascular diseases, autoimmune diseases and viral infections